BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Implanon NXT®: Possible risks and complications associated with insertion, localisation, removal and migration

2016.06.27

Active substance: etonogestrel

The company MSD Sharp & Dohme GmbH recommends that only those physicians should insert and remove Implanon NXT® who have completed training for the use of the NXT® applicator and techniques for insertion and removal of the Implanon NXT® implant.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 1MB, File does not meet accessibility standards